Genmab (GMAB)
(Delayed Data from NSDQ)
$28.24 USD
-0.11 (-0.39%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $28.24 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.24 USD
-0.11 (-0.39%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $28.24 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Zacks News
4 Top Stocks to Buy on Earnings Beat Potential
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next releases. These stocks include Genmab (GMAB), Hologic (HOLX), ServiceNow (NOW) and Splunk (SPLK).
GILD or GMAB: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GILD vs. GMAB: Which Stock Is the Better Value Option?
New Strong Buy Stocks for January 11th
by Zacks Equity Research
GMAB, OSW, ACDC, EVBG and MTG have been added to the Zacks Rank #1 (Strong Buy) List on January 11 , 2023.
Ensign Group (ENSG) Unveils Dividend Hike to Reward Shareholders
by Zacks Equity Research
Ensign Group's (ENSG) latest dividend hike reflects strong financial standing and intensified focus in the tactical deployment of capital.
LGND or GMAB: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. GMAB: Which Stock Is the Better Value Option?
Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Ensign Group (ENSG) Facility Buyout to Boost Colorado Foothold
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in Colorado that are likely to grow its healthcare portfolio and solidify its nationwide presence.
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Oncolytics Biotech Inc. (ONCY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com featured highlights include Tap Genmab, KnowBe4, UserTesting, Enphase Energy and Gartner
by Zacks Equity Research
Tap Genmab, KnowBe4, UserTesting, Enphase Energy and Gartner are part of the Zacks Screen of the Week article.
5 Top Stocks to Tap Earnings Beat Potential
by Sanghamitra Saha
Buy shares of Genmab (GMAB), KnowBe4 (KNBE), UserTesting (USER), Enphase Energy (ENPH) and Gartner (IT).
Here's What's Driving AbbVie's (ABBV) Outperformance This Year
by Zacks Equity Research
AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.
AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag
by Zacks Equity Research
The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.
Humana's (HUM) Arm to Aid Senior Care, 2023 Expansion on Track
by Zacks Equity Research
Humana's (HUM) CenterWell brand plans to open centers in untapped markets as well as dig deeper into the existing regions offering enhanced primary care services to the nation's senior citizens.
Can Genmab AS Sponsored ADR (GMAB) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Genmab AS Sponsored ADR (GMAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PBYI vs. GMAB: Which Stock Is the Better Value Option?
Is Genmab (GMAB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Genmab AS Sponsored ADR (GMAB) and Nuvalent, Inc. (NUVL) have performed compared to their sector so far this year.
Is a Surprise Coming for Genmab (GMAB) This Earnings Season?
by Zacks Equity Research
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Sundeep Ganoria
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
Centene (CNC) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Centene's (CNC) third-quarter results are likely to reflect higher premiums and contract wins enjoyed by its Medicaid business, partly offset by escalating operating expenses.
INCY vs. GMAB: Which Stock Is the Better Value Option?
by Zacks Equity Research
INCY vs. GMAB: Which Stock Is the Better Value Option?
Will UnitedHealth Group (UNH) Beat Q3 Earnings Estimates?
by Zacks Equity Research
UnitedHealth Group's (UNH) third-quarter results are likely to benefit from higher premiums and membership growth in its UnitedHealthcare unit, partly offset by elevated technology investment costs.
Should You Buy Genmab (GMAB) Ahead of Earnings?
by Zacks Equity Research
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.